FRANCISCO DE ASIS AYALA DE LA PEÑA

Garcia-Torralba E, Navarro Manzano E, Luengo-Gil G, De la Morena Barrio P, Chaves Benito A, Perez-Ramos M, Alvarez-Abril B, Ivars Rubio A, Garcia-Garre E, Ayala de la Pena F, Garcia-Martinez E. A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients. Front Oncol. 2023 May 29;13:1182725. doi: 10.3389/fonc.2023.1182725. eCollection 2023. PubMed PMID: 37313470; PubMed Central PMCID: PMC10258327.

AÑO: 2023; IF: 4.7

37313470

Bueno-Muino C, Echavarria I, Lopez-Tarruella S, Roche-Molina M, Del Monte-Millan M, Massarrah T, Jerez Y, Ayala de la Pena F, Garcia-Saenz JA, Moreno F, Rodriguez-Lescure A, Malon-Gimenez D, Ballesteros Garcia AI, Marin-Aguilera M, Galvan P, Braso-Maristany F, Waks AG, Tolaney SM, Mittendorf EA, Vivancos A, Villagrasa P, Parker JS, Perou CM, Pare L, Villacampa G, Prat A, Martin M. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. JAMA Oncol. 2023 Jun 1;9(6):841-846. doi: 10.1001/jamaoncol.2023.0187. PubMed PMID: 37103916; PubMed Central PMCID: PMC10141274.

AÑO: 2023; IF: 28.4

37103916

Garcia-Torralba E, Perez Ramos M, Ivars Rubio A, Navarro-Manzano E, Blaya Boluda N, de la Morena Barrio P, Garcia-Garre E, Martinez Diaz F, Chaves-Benito A, Garcia-Martinez E, Ayala de la Pena F. Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (sTIL) in Early Luminal B Breast Cancer. Cancers (Basel). 2023 May 20;15(10):2846. doi: 10.3390/cancers15102846. PubMed PMID: 37345183; PubMed Central PMCID: PMC10216816.

AÑO: 2023; IF: 5.2

37345183

Ayala de la Pena F, Antolin Novoa S, Gavila Gregori J, Gonzalez Cortijo L, Henao Carrasco F, Martinez Martinez MT, Morales Estevez C, Stradella A, Vidal Losada MJ, Ciruelos E. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022). Clin Transl Oncol. 2023 Sep;25(9):2647-2664. doi: 10.1007/s12094-023-03215-4. Epub 2023 Jun 16. PubMed PMID: 37326826; PubMed Central PMCID: PMC10425528.

AÑO: 2023; IF: 3.4

37326826

Castillo-Guardiola V, Rosado-Jimenez L, Sarabia-Meseguer MD, Marin-Vera M, Macias-Cerrolaza JA, Garcia-Hernandez R, Zafra-Poves M, Sanchez-Henarejos P, Moreno-Locubiche MA, Cuevas-Tortosa E, Arnaldos-Carrillo M, Ayala de la Pena F, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance. Eur J Med Genet. 2022 Apr;65(4):104468. doi: 10.1016/j.ejmg.2022.104468. Epub 2022 Mar 1. PubMed PMID: 35245693.

AÑO: 2022; IF: 1.9

35245693